Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer.

Onco Targets Ther · 2013 · PMC3589083 · PMID 23467839

Europe PMC DOI

hedged sentence

0.1340

closest p · 2.7× alpha

0.1340

boldest claim

The sentences

did not reach statistical significanceP = 0.134not close (p > 0.1)

Although subgroup analysis of overall survival seemed to favor patients with EGFR-mutated tumors compared with wild-type EGFR tumors, the difference did not reach statistical significance ( P = 0.134, Figure 7 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.